Inflammation and Hras signaling control epithelial–mesenchymal transition during skin tumor progression

  1. Allan Balmain1,5
  1. 1Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California 94158, USA;
  2. 2Department of Radiation Oncology,
  3. 3Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA;
  4. 4Department of Pathology, University of California at San Francisco, San Francisco, California 94143, USA

    Abstract

    Epithelial–mesenchymal transition (EMT) is thought to be an important, possibly essential, component of the process of tumor dissemination and metastasis. About 20%–30% of Hras mutant mouse skin carcinomas induced by chemical initiation/promotion protocols have undergone EMT. Reduced exposure to TPA-induced chronic inflammation causes a dramatic reduction in classical papillomas and squamous cell carcinomas (SCCs), but the mice still develop highly invasive carcinomas with EMT properties, reduced levels of Hras and Egfr signaling, and frequent Ink4/Arf deletions. Deletion of Hras from the mouse germline also leads to a strong reduction in squamous tumor development, but tumors now acquire activating Kras mutations and exhibit more aggressive metastatic properties. We propose that invasive carcinomas can arise by different genetic and biological routes dependent on exposure to chronic inflammation and possibly from different target cell populations within the skin. Our data have implications for the use of inhibitors of inflammation or of Ras/Egfr pathway signaling for prevention or treatment of invasive cancers.

    Keywords

    Footnotes

    • Received November 15, 2012.
    • Accepted February 22, 2013.
    | Table of Contents

    Life Science Alliance